- $116.26m
- $145.26m
- $94.64m
Societal CDMO Inc reports results for the quarter ended in March - Earnings Summary
Brief: Societal Cdmo Reports Qtrly Loss Per Share $0.06
Societal CDMO Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Societal Cdmo Selected By Xequel Bio To Provide Cdmo Services To Support Ongoing Clinical Development Of Inexin
Brief: Cingulate Announces Successful Transfer Of Ctx-1301 (Dexmethylphenidate) Proprietary Ptr™ Manufacturing Processes To Societal Cdmo
Brief: Societal CDMO Signs Multiple Project Expansion Agreements With Customers
Brief: Societal Cdmo Selected By Longboard Pharmaceuticals To Provide Cdmo Services To Support Clinical Development Of Lp352
Brief: Societal CDMO - On March 23, Michael Berelowitz, Notified Co Of His Intent Not To Stand For Re-Election To Board At Co's 2023 Annual Meeting Of Shareholder
U.S. STOCKS ON THE MOVE-CalciMedica, Natgas firms,
U.S. STOCKS ON THE MOVE-ReNew Energy, First Horizon, Block Inc
RBC optimistic on Societal CDMO's growth prospects; starts with 'outperform'
U.S. RESEARCH ROUNDUP- General Mills, McDonald's, Wells Fargo & Co
Brief: Societal CDMO Announces U.S. FDA Approval For Manufacturing Of Commercial Tablet At Georgia Site
Brief: Societal CDMO Holds No Cash Deposits Or Securities With SVB
Societal CDMO Inc reports results for the quarter ended in December - Earnings Summary
Brief: Societal Cdmo Reports Fourth Quarter And Full Year 2022 Financial Results
Societal CDMO Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Societal CDMO Signs Over $6 Mln In Work Orders During Q4
Brief: Societal CDMO Completes Strategic Recast Of Capital Structure Highlighted By Reduction And Refinancing Of Outstanding Debt